You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD47

Showing 1 - 25 of 2,804
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer of the Colon Trial in Marseille (BLOOD AND TUMOR)

Recruiting
  • Cancer of the Colon
  • BLOOD AND TUMOR
  • Marseille, France
    Institut Paoli Calmettes
Jul 12, 2023

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jul 17, 2023

Patients With Recurrent Acute Myelogenous Leukemia After Transplantation Trial in Suzhou (CD47 mAb)

Recruiting
  • Patients With Recurrent Acute Myelogenous Leukemia After Transplantation
  • CD47 monoclonal antibody
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Mar 3, 2022

Relapsed/Refractory Lymphoma Trial in Beijing (Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection)

Recruiting
  • Relapsed/Refractory Lymphoma
  • Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Jan 10, 2022

Advanced Malignant Tumor Trial in Guangzhou (BAT7104 injection)

Recruiting
  • Advanced Malignant Tumor
  • BAT7104 injection
  • Guangzhou, Guangdong, China
    Li Zhang
Mar 1, 2023

Advanced Solid Tumors Trial in Beijing (HX009)

Active, not recruiting
  • Advanced Solid Tumors
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Feb 7, 2023

Hematological Malignancy, Lymphoma Trial in Canton (SG2501)

Recruiting
  • Hematological Malignancy
  • Lymphoma
  • Canton, Ohio
    Gabrail Cancer Center Research, LLC
Aug 3, 2022

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

Active, not recruiting
  • Pyoderma
  • +3 more
  • Monoclonal antibody (Mab) sB24M
  • Minsk, Belarus
  • +1 more
Jul 8, 2022

P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)

Not yet recruiting
  • P47-Phox, Deficiency of
  • Lentiviral vector transduced CD34+ cells
  • London, United Kingdom
    Great Ormond Street Hospital
Aug 2, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Apr 10, 2023

Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer Trial in Paris, Rennes, Milano

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • NI-1801
  • Paris, France
  • +4 more
Nov 4, 2022

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

Erythema, Rosacea Trial in United States (CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%)

Completed
Has Results
  • Erythema
  • Rosacea
  • CD07805/47 gel 0.5%/CD07805/47 Vehicle
  • azelaic acid gel 15%
  • Evansville, Indiana
  • +3 more
Jul 28, 2022

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Chemotherapy)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jan 27, 2022

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Carboplatin)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 10, 2022

Solid Tumor, Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (Gentulizumab)

Recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Shanghai, Shanghai, China
  • +1 more
Jan 21, 2022

Myelodysplastic Syndrome Trial in Suzhou (AK117, Azacitidine)

Recruiting
  • Myelodysplastic Syndrome
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 21, 2021

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Acute Myeloid Leukemia Trial in Hangzhou (AK117, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，Zhejiang University School of Medi
Jul 21, 2021

Advanced Malignant Tumors Lymphomas Trial in United States (IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody

Recruiting
  • Advanced Malignant Tumors Lymphomas
  • IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
  • Los Angeles, California
  • +3 more
Aug 23, 2022

Solid Tumor, Relapsed Solid Tumor, Refractory Tumor Trial in United States (STI-6643)

Recruiting
  • Solid Tumor
  • +2 more
  • STI-6643
  • San Diego, California
  • +4 more
Jun 30, 2022